Download PDF
Metabolism and Nutrition in Oncology 2013; 01(01): e7-e11
DOI: 10.1055/s-0033-1358760
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Retrospective Study of Body Weight in Patients with Multiple Myeloma through Different Stages of the Disease

G. Talamo
1   Milton S. Hershey Medical Center, Hershey, PA, USA
,
J. Zhu
1   Milton S. Hershey Medical Center, Hershey, PA, USA
,
N. G. Dolloff
1   Milton S. Hershey Medical Center, Hershey, PA, USA
,
N. E. Lamparella
1   Milton S. Hershey Medical Center, Hershey, PA, USA
,
M. Joshi
1   Milton S. Hershey Medical Center, Hershey, PA, USA
,
A. Barochia
1   Milton S. Hershey Medical Center, Hershey, PA, USA
,
J. J. Drabick
1   Milton S. Hershey Medical Center, Hershey, PA, USA
,
J. Malysz
1   Milton S. Hershey Medical Center, Hershey, PA, USA
› Author Affiliations
Further Information

Publication History

received 24 March 2013

accepted 01 November 2013

Publication Date:
16 December 2013 (online)

   Permissions and Reprints

Abstract

Background:

Little is known regarding body weight changes in patients with multiple myeloma (MM) during the course of their disease, and the influence of obesity in the overall survival (OS) of patients affected by this cancer.

Methods:

We retrospectively collected clinical data from 318 MM patients, and analyzed their weight and body mass index (BMI) at various points throughout the course of the disease, including baseline, pre- and post-peripheral blood stem cell transplant (PBSCT), and time of death.

Results:

At the time of diagnosis, median BMI was 28.1 (±5.7 SD; range, 15.3–51.8). The majority of MM patients were either overweight or obese, both at the time of initial diagnosis (80%) and in the terminal phase of the disease (66%). Only 5% of patients had malnutrition at the time of death. Median body weight was 81.5 and 79.4 kg before and 6 weeks after high-dose chemotherapy and PBSCT (p<0.001). Kaplan-Meier estimates of OS showed similar results between patients with normal weight and obese patients.

Conclusions:

The majority of MM patients, at least in our cohort of U.S. residents, are either overweight or obese. Despite the common notion that the terminal phase of cancer is associated with cachexia, most MM patients did not experience a significant and progressive weight loss. PBSCT was associated with a statistically significant but clinically negligible weight loss. Obesity did not seem to influence overall survival in MM.

Key words

body weight - obesity - overweight - cachexia - multiple myeloma - stem cell transplant
 

  • References

  • 1 Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236
    CrossrefPubMedGoogle Scholar
  • 2 Perez Perez A, Ybarra Munoz J, Blay Cortes V, de Pablos Velasco P. Obesity and cardiovascular disease. Public Health Nutr 2007; 10: 1156-1163
    PubMedGoogle Scholar
  • 3 Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578
    CrossrefPubMedGoogle Scholar
  • 4 Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010; 15: 556-565
    CrossrefPubMedGoogle Scholar
  • 5 Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591
    CrossrefPubMedGoogle Scholar
  • 6 Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer 2011; 47: 1606-1615
    CrossrefPubMedGoogle Scholar
  • 7 Larsson SC, Wolk A. Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer 2007; 121: 2512-2516
    CrossrefPubMedGoogle Scholar
  • 8 Landgren O, Rajkumar SV, Pfeiffer RM, Kyle RA, Katzmann JA, Dispenzieri A, Cai Q, Goldin LR, Caporaso NE, Fraumeni JF, Blot WJ, Signorello LB. Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 2010; 116: 1056-1059
    CrossrefPubMedGoogle Scholar
  • 9 Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200
    CrossrefPubMedGoogle Scholar
  • 10 Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U, Waage A, Iversen PO. Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol 2009; 83: 460-470
    CrossrefPubMedGoogle Scholar
  • 11 Hofmann JN, Liao LM, Pollak MN, Wang Y, Pfeiffer RM, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N, Purdue MP. A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood 2012; 120: 4418-4420
    CrossrefPubMedGoogle Scholar
  • 12 Use and interpretation of anthropometric indicators of nutritional status . WHO Working Group. Bull World Health Organ 1986; 64: 929-941
    PubMedGoogle Scholar
  • 13 Physical status: the use and interpretation of anthropometry . Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995; 854: 1-452
    PubMedGoogle Scholar
  • 14 Norton JA, Peacock JL, Morrison SD. Cancer cachexia. Crit Rev Oncol Hematol 1987; 7: 289-327
    CrossrefPubMedGoogle Scholar
  • 15 Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-495
    CrossrefPubMedGoogle Scholar
  • 16 Nikolousis E, Nagra S, Paneesha S, Delgado J, Holder K, Bratby L, Chaganti S, Lovell R, Milligan D. Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies. Ann Hematol 2010; 89: 1141-1145
    CrossrefPubMedGoogle Scholar
  • 17 Vogl DT, Wang T, Perez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2011; 17: 1765-1774
    CrossrefPubMedGoogle Scholar
  • 18 Kraschnewski JL, McCall-Hosenfeld JS, Weisman CS. Prospective association between body mass index and receipt of preventive services: results from the Central Pennsylvania Women's Health Study (CePAWHS). Prev Med 2012; 54: 302-305
    CrossrefPubMedGoogle Scholar
  • 19 Patel AV, Diver WR, Teras LR, Birmann BM, Gapstur SM. Body mass index, height, and risk of lymphoid neoplasms in a large US cohort. Leuk Lymphoma 2013; 54: 1221-1227
    CrossrefPubMedGoogle Scholar
  • 20 Blair CK, Cerhan JR, Folsom AR, Ross JA. Anthropometric characteristics and risk of multiple myeloma. Epidemiology 2005; 16: 691-694
    CrossrefPubMedGoogle Scholar
  • 21 Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2007; 16: 1474-1478
    CrossrefPubMedGoogle Scholar
  • 22 Fernberg P, Odenbro A, Bellocco R, Boffetta P, Pawitan Y, Zendehdel K, Adami J. Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. Cancer Res 2007; 67: 5983-5986
    CrossrefPubMedGoogle Scholar
  • 23 Kuczmarski MF, Kuczmarski RJ, Najjar M. Effects of age on validity of self-reported height, weight, and body mass index: findings from the Third National Health and Nutrition Examination Survey, 1988–1994. J Am Diet Assoc 2001; 101: 28-34
    CrossrefPubMedGoogle Scholar